Selected publications (2010-2022). Please see the PubMed for full list.

Wang Y, Huang P, Wang BG, Murdock T, Cope L, Hsu FC, Wang TL, Shih IM. Spatial transcriptomic analysis of ovarian cancer precursors reveals reactivation of IGFBP2 during pathogenesis. Cancer Res, 82:4528-4541, 2022. PMID: 36206311

Asaka S, Liu Y, Yu ZC, Suryo Rahmanto Y, Ono M, Asaka R, Miyamoto T, Yen TT, Ayhan A, Wang TL, Shih IM. ARID1A regulates progesterone receptor expression in early endometrial endometrioid carcinoma pathogenesis. Mod Pathol, 36: 100045, 2023. PMID: 36853791

Lee MH, Russo G, Suryo Rahamannto Y, Do W, Crawford AJ, Wu PH, Gilkes D, Kiemen A, Miyamoto T, Yu Y, Habib M, Shih IM, Wang TL, Wirtz D. Multi-compartment organoids. Material Today, 2022.

Vang R. Shih IM. Serous tubal intraepithelial carcinoma: what do we really know at this point? Histopathology, https://doi.org/10.1111/his.14722. 2022. PMID: 35859323

Mandal J, Mandal P, Wang TL, Shih IM. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J Biol Sci, 29:71, 2022. doi: 10.1186/s12929-022-00856-5. PMID: 36123603

Li L, Antero MF, Zhang M, Chu T, Seckin T, Ayhan A, Pisanic T, Wang TL, Cope L, Segars J, Shih IM. Mutation- and methylation-profiles of ectopic and eutopic endometrial epithelium. J Pathol, 255:387-398, 2021. PMID: 34396532

Shen YA, Jung J, Shimberg GD, Hus fc, Rahmanto YS, Gaillard SL, Jong J, Bosch J, Shih IM, Chuang CM, Wang TL. Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy. iScience, 24:103297, 2021. PMID: 34816098

Shih IM, Wang Y, Wang TL. The origin of ovarian cancer species and the precancerous landscape. Am J Pathol, 2021. PMID: 33011111

Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Rahmanto Y, Jung JG, Chen YW, Yen TT, Tomaszewski A, Zhang C, Attarwata N, DeMarzo AM, Davidson B, Chuang CM, Chen X, Gaillard S, Le A, Shih IM, Wang TL. Inhibition of the MUC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant cancers. Cancer Res, 2020. PMID: 32859605.

Pisanic TR, Wang Y, Sun H, Considine M, Li L, Wang TH, Wang TL, Shih IM. The methylomic landscape of fallopian tube lesions associated with ovarian high-grade serous carcinoma. Clin Cancer Res, 2020. PMID: 32817081

Rahmanto YS, Shen W, Shi X, Chen X, Yu Y, Yu C, Miyamoto T, Asaka R, Lee MH, Singh V, Shimberg G, Vitolo MI, Martin SS, Wirtz D, Drapkin R, Xuan J, Wang TL, Shih IM. Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nature Comm, 11:2717, 2020. PMID: 32483112

Wang Y, Nicholes K, Shih IM. The origin and pathogenesis of endometriosis.  Ann Rew Pathol, 15:71:95, 2020. PMID: 31479615

Varghese A, Shih IM. Editorial: Not all peritoneal implants are created equal. Gyn Oncol, 156:1-2, 2020. PMID: 31954499

Chui MH, Shih IM. Oncogenic BRAF and KRAS mutations in endosalpingiosis. J Pathol, 250:148-158, 2020. PMID: 31576556

Douville C, Cohen JD, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Schoen RE, Tie J, Gibbs P, Goggins M, Wolfgant CL, Wang TL, Shih IM, Karchin R, Lennon AM, Hruban RH, Tomasetti C, Bettegowda C, Kinzler KW, Papadopoulos N, Vogelstein B. Assessing aneuploidy with repetitive element sequencing. Proc Natl Acad Sci, 117:4858-4863, 2020. PMID: 32075918

Park Y, Chui MH, Rahmanto YS, Shamanna RA, Bellani W, Yu ZC, Gaillard S, Ayhan A, Viswanathan A, Seidman MM, Franco S, Leung A, Bohr VA, Shih IM, Wang TL. Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy. Clin Can Res, 2019. PMID: 31196855

Yu Y, Rahmanto YS, Shen YA, ARdighieri L, Davidson B, Gaillard S, Ayhan A, Shi X, Xuan J, Wang TL, Shih IM. Spleen tyrosine kinase activity regulates epidermal growth factor receotpr signaling pathway in ovarian cancer. EBioMedicine, 47:184-194, 2019. PMID: 31492560

Pisanic TR, Asaka S, Lin SF, Yen TT, Sun H, Bahadirli-Talbott A, Wang TH, Burns KH, Wang TL, Shih IM. LINE-1 retrotransposons become deregulated during the development of ovarian cancer precursor lesions. Am J Pathol, 189:513-520, 2019. PMID: 30553834

Asaka S, Davis C, Lin SF, Wang TL, Heaphy CM, Shih IM. Analysis of telomere lengths in p53 signatures and incidental serous tubal intraepithelial carcinomas without concurrent ovarian cancer. Am J Surg Pathol, in press, 2019. PMID: 31107721.

Wu RC, Wang P, Lin SF, Zhang M, Song Q, Chu T, Wang BG, Kurman RJ, Vang R, Kinzler K, Tomasetti C, Jian Y, Shih IM, Wang TL. Genomic landscape and evolutionary trajectories of ovarian cancer early precursor lesions. J Pathol, 248:41-50, 2019. PMID: 30560554

Visvanathan K, Shaw PA, May BJ, Bahadirli-Talbot A, Kaushiva A, Risch HA, Narod SA, Wang TL, Parkash V, Vang R, Levine DA, Soslow RA, Kurman RJ, Shih IM. Fallopian tube lesions in women at high risk for ovarian cancer: a multicenter study. Can Prev Res, 11:697-706, 2018. PMID: 30232083

Hu Z, Zhou J, Jiang J, Yuan J, Zhang Y, Wei X, Loo N, Wang Y, Pan Y, Zhang T, Zhong X, Long M, Montone KT, Tanyi JL, Fan Y, Wang TL, Shih IM, Hu X, Zhang L. Nat Commun, 10:733, 2019. PMID: 30760718

Pisanic TR, Lin SF, Yen TT, Athamanolap P, Nakayama K, Cope LM, Wang TH, Shih IM, Wang TL. Methylomic analysis of ovarian cancers identifies tumor-specific alterations readily detectable in early precursor lesions. Clin Cancer Res, 2018. PMID: 30108013

Yu Y, Rahmanto YS, Lee MH, Wu PH, Phillip JM, Huang CH, Vitolo MI, Gaillard S, Martin SS, Wirtz D, Shih IM, Wang TL. Inhibition of ovarian tumor cell invasiveness by targeting SYK in tyrosine kinase pathway. Oncogene, 37:3778-3789, 2018. PMID: 29643476

Noe M, Ayhan A, Wang TL, Shih IM. Independent development of endometrial epithelium and stroma within the same endometriosis. J Pathol, 245:265-269, 2018. PMID: 29604057

Visvanathan K, Wang TL, Shih IM. Pre-cancerous lesions of ovarian cancer- a US perspective. J Natl Can Inst, 110:692-693, 2018. PMID: 29281080

Angeleso M, Papdopoulos N, Ayhan A, Wang TL, Nazeran TM, Horlings HM, Noe M, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen, J, Wong F, Hasanovic A, Orr, Wang M, Popoli M, McMahon W, Wood L, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks B, Diza L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM. Cancer associated mutations in endometriosis without cancer. N Engl J Med, 376:185-1848, 2017. PMID: 28489996

Lin SF, Gerry E, Shih IM. Tubal origin of ovarian cancer- the double-edged sword of haemaglobin. J Pathol, 242:3-6, 2017. PMID: 28054715

Ayhan A, Kuhn E, Wu RC, Ogawa H, Talbott AB, Mao TL, Sugimura H, Shih IM, Wang TL. CCNE1 copy number gain and overexpression identifies ovarian clear cell carcinoma with a poor prognosis. Mod Path, 30:297-303, 2017. PMID: 27767100

Wu RC, Veras E, Lin J, Gerry E, Bahadirli-Talbott A, Shih IM, Wang TL. Elucidating the pathogenesis of synchronous and metachronous tumors in a   woman with endometrioid carcinoma using a whole-exome sequencing approach. Cold Spring Harbor Mol Case Studies. 3:E001693, 2017. PMID: 29162652

Jung JG, Shih IM, Park JT, Gerry E, Kim TH, Ayhan A, Handshuh K, Davidson B, Fader AN, Selleri L, Wang TL. The expression of PBX1, a stem cell reprogramming factor, in ovarian cancer chemoresistance. Cancer Res, 76:6351-61, 2016. PMID: 27590741

Rahmanto YS, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IM. Inactivating ARID1A tumor suppressor enhances hTERT transcription and maintains telomere length in cancer cells. J Biol Chem, 291:9690-9699, 2016. PMID:26953344

Kurman RJ, Shih IM. The Dualistic Model of Ovarian Carcinogenesis. Revisited, Revised and Expanded.  Am J Pathol, 186: 733:747, 2016. PMID:27012190

Yu Y, Gaillard S, Jude MP, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, Davidson B, Wang TL, Shih IM.  Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell, 28:82-96, 2015. PMID: 26096845

Kobayashi Y, Kashima H, Wu RC, Jung J, Kuan JC, Gu J, Xuan J, Visvanathan K, Shih IM, Wang TL. Mevalonate pathway antagonist inhibits proliferation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models. Clin Cancer Res, 21:4652-62, 2015. PMID: 26109099

Ju J, Kapoor P, Shen X, Shih IM, Peng G. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discovery, 5:752-767, 2015. PMID: 26096845

Ayhan A, Mao TL, Rahmanto YS, Ogawa H, Wu RC, Wang TL, Shih IM. Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of endometrium with concurrent inactivation of ARID1A and PTEN tumor suppressors. J Pathol Clin Res, 1:186-193, 2015.

Jung J, Stoeck A, Guan B, Wu RC, Zhu H, Blackshaw S, Shih IM, Wang TL. Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer. PLoS Genetics, 10:e1004751, 2014. PMID:25356737

Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL, Shih IM. The roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst, June 4; 106(7).  doi: 10.1093/jnci/dju146 (July issue). 2014. PMID:24899687

Wu RC, Wang TL, Shih IM. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther, 15:655-664, 2014. PMID:24618703

Yang YI, Ahn JH, Lee KT, Shih IM, Choi JH. RSF-1 is a positive regulator of NFkB-induced gene expression required for ovarian cancer chemoresistance. Cancer Res, 74:2258-2269, 2014. PMID:24566868

Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chiu MH, Rosen B, Shih IM, Wang TL. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynecologic malignancies. J Pathol, 232:473-481, 2014. PMID:24338723.

Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IM. Mutational analysis of BRAF and KRAS in ovarian atypical proliferative serous (borderline) tumors and associated peritoneal implants. J Pathol, 232:16-22, 2014.  PMID:24307542

Gao M, Uw RC, Herlinger AL, Yap K, Kim JW, Wang TL, Shih IM. Identification of NAC1-regulated genes in ovarian cancer. Am J Pathol, 184:133-140, 2014. PMID:24200849

Sheu J, Choi JH, Guan B, Tsai FJ, Hua CH, Lai MT, Wang TL, Shih IM. Rsf-1, a chromatin remodeling protein, interacts with cyclin E1 and promotes tumor development. J Pathol, 229:559-568, 2013. PMID:23378270

Kuhn E, Wu RC, Wu G, Guan B, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RBS, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Levine DA, Kurman RJ, Wang TL, Shih IM. Genome-wide analyses of uterine serous carcinoma identify pathway aberrations involving cyclin E-Fbxw7, PI3K and p53. J Natl Cancer Inst, 104:1503-1513, 2012. PMID:22923510

Yap KL, Fraley SI, Thiaville MM, Jinawath N, Nakayama K, Wang J, Wang TL, Wirtz D, Shih IM. NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells. Cancer Res, 72:4085-4096, 2012. PMID:22761335

Chen X, Gao M, Xuan J, Chen L, Thiaville M, Stoeck A, Shih IM, Wang TL. Definition of NOTCH3 target genes in ovarian cancers. Cancer Res, 2012; 72 2294-2303. PMID: 22396495

Sheu JJC, Guan b, Tsai FJ, Hsia YT, Chen CM, Wang TL, Shih IM. Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway and upregulates glucose transporter-1 in non-transformed epithelial cells. Am J Pathol, 180:1179-1188, 2012. PMID: 22227015

Zhang Y, Cheng Y, Ren X, Zhang L, Yap KL, Wu H, Patel R, Liu D, Qin ZH, Shih IM, Yang JM. NAC1 modulates sensitivity of ovarian cancer cells to cisplatin via altering the HMGB1-mediated autophagic response. Oncogene, 31:1055-1064, 2012. (co-corresponding author) PMID:21743489

Jones S*, Wang TL*, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih IM. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol, 226:413-420, 2012. PMID:22102435 (with cover illustration)

Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih IM. TP53 mutations in serous tubal intraepithelial carcinoma (STIC) and concurrent pelvic high-grade serous carcinoma- evidence supporting their clonal relationship. J Pathol, 226:421-426, 2012.  PMID:21990067

Guan B, Wang TL, Shih IM. The tumor suppressor role of ARID1A in gynecological cancer. Cancer Res, 71:6718-6727, 2011. PMID: 21900401

Shih IM, Wang TL. Mutation in PPP2R1A- a new clue in unveiling thepathogenesis of uterine serous carcinoma. J Pathol, 223:567-573, 2011. PMID: 21432855

Shih IM, Panuganti PK, Kuo KT, Mao TL, Kuhn E, Jones J, Velculescu VE, Kurman R, Wang TL. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol, 178: 1442-1447, 2011. PMID: 21435433

Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz L, Vogelstein B,, Kinzler KW, Velculescu VE,  Papadopoulos N. Exomic sequences of ovarian clear cell carcinomas. Science, 330:228-231, 2010. PMID: 20826764

Sheu JJ, Guan B, Choi JH, Lin A, Lee CH, Hsiao YI, Wang TL, Tsai FJ. Shih IM. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem, 285:38260-38269, 2010. PMID: 20923775

Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, Glas R, Ma J, Kurman RJ, Shih IM, Wang TL.  DNA copy number profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res, 16:1997-2008, 2010.  PMID: 20233889

Park J, Xu C, Trope CG, Davidson B, Shih IM, Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol, 177:1087-1094, 2010. PMID: 20671266